{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:45:39Z","timestamp":1793659539011,"version":"4.5.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The course of hereditary angioedema (HAE) during pregnancy varies greatly. Limited treatment options complicate the management of HAE in this period. This study aimed to examine the clinical progression of HAE throughout the perinatal period in relation to management strategies. Additionally, we reported the first documented case of Lanadelumab (Takhzyro) therapy during pregnancy in a patient with HAE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We performed an observational study at the University Hospital Zurich (a tertiary treatment center), in which we included 7 HAE female HAE patients. We analyzed 15 pregnancies of these women. The average maternal age at delivery was 33\u2009years (range: 21\u201341), and the average gestational age was 40\u2009+\u20093\/7\u2009weeks. Fourteen deliveries were spontaneous, with one requiring vacuum extraction. There were no miscarriages during the study period. Maternal C1-INH levels averaged 0.09\u2009g\/l (range: 0.04\u20130.16), and functional activity averaged 28% (range: 17\u201342%). Of the 15 newborns, 8 were HAE-positive. Their mean birth weight was 3170\u2009g (\u00b1546), compared to 3618\u2009g (\u00b1225) in HAE-negative children. No significant complications or adverse outcomes were observed in either group. Attack frequency during pregnancy increased in 4 cases, decreased in 7, and remained unchanged in 4. Most women (60%) received plasma-derived C1-inhibitor (Berinert) for acute management; 27% used it prophylactically during pregnancy. One patient received combination therapy with Lanadelumab\/Takhzyro\u00ae and Berinert\u00ae, showing good tolerability and effectiveness. The pregnancy proceeded without complications and the child was born healthy at term with normal birth weight.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The variable evolution of HAE symptoms during pregnancy highlights the need for flexible and personalized treatment plans. Plasma-derived C1-inhibitor remains the recommended treatment during pregnancy due to its favorable therapeutic and safety profile. The first documented use of Lanadelumab during pregnancy was well tolerated and linked to positive outcomes for both mother and newborn. Although these findings are promising, further research is necessary to confirm the safety and effectiveness of Lanadelumab in this setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04280-y","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T09:46:37Z","timestamp":1771667197000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Management of pregnancy, delivery and breast-feeding in hereditary angioedema: an analysis of 15 pregnancies with conventional treatment approaches and a case of Lanadelumab use"],"prefix":"10.1186","volume":"21","author":[{"given":"Marine","family":"Casanova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Charlotte","family":"Br\u00fcggen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter Alfred","family":"Wuillemin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3671-8079","authenticated-orcid":false,"given":"Christina","family":"Weber-Chrysochoou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,21]]},"reference":[{"key":"4280_CR1","doi-asserted-by":"crossref","unstructured":"Busse PJ, Christiansen SC. Hereditary Angioedema N Engl J Med. 2020;382(12):1136\u201348.","DOI":"10.1056\/NEJMra1808012"},{"key":"4280_CR2","first-page":"103","volume":"7","author":"A Ghazi","year":"2013","unstructured":"Ghazi A, Grant JA. Hereditary angioedema: epidemiology, management, and role of icatibant. Biologics. 2013;7:103\u201313.","journal-title":"Biologics"},{"issue":"7","key":"4280_CR3","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1111\/all.15214","volume":"77","author":"M Maurer","year":"2022","unstructured":"Maurer M, et al. The international WAO\/EAACI guideline for the management of hereditary angioedema-the 2021 revision and update. Allergy. 2022;77(7):1961\u201390.","journal-title":"Allergy"},{"issue":"2","key":"4280_CR4","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s12016-016-8543-x","volume":"51","author":"AE Germenis","year":"2016","unstructured":"Germenis AE, Speletas M. Genetics of hereditary angioedema revisited. Clin Rev Allergy Immunol. 2016;51(2):170\u201382.","journal-title":"Clin Rev Allergy Immunol"},{"key":"4280_CR5","unstructured":"Kulkarni M, Travers JB, Rohan C. High estrogen states in hereditary angioedema: a spectrum."},{"issue":"7","key":"4280_CR6","doi-asserted-by":"publisher","first-page":"391","DOI":"10.12968\/hmed.2019.80.7.391","volume":"80","author":"HJ Longhurst","year":"2019","unstructured":"Longhurst HJ, Bork K. Hereditary angioedema: an update on causes, manifestations and treatment. Br J Hosp Med (Lond). 2019;80(7):391\u201398.","journal-title":"Br J Hosp Med (Lond)"},{"issue":"1","key":"4280_CR7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/0091-6749(80)90181-5","volume":"65","author":"A Agostoni","year":"1980","unstructured":"Agostoni A, et al. Danazol and stanozolol in long-term prophylactic treatment of hereditary angioedema. J. Allergy Clin. Immunol. 1980;65(1):75\u201379.","journal-title":"J. Allergy Clin. Immunol"},{"issue":"4","key":"4280_CR8","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/j.0954-6820.1972.tb04818.x","volume":"192","author":"G Blohm\u00e9","year":"1972","unstructured":"Blohm\u00e9 G. Treatment of hereditary angioneurotic oedema with tranexamic acid. A random double-blind cross-over study. Acta Med Scand. 1972;192(4):293\u201398.","journal-title":"Acta Med Scand"},{"issue":"3","key":"4280_CR9","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jaci.2012.05.055","volume":"130","author":"K Bork","year":"2012","unstructured":"Bork K, Hardt J, Witzke G. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J. Allergy Clin. Immunol. 2012;130(3):692\u201397.","journal-title":"J. Allergy Clin. Immunol"},{"issue":"2","key":"4280_CR10","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S1081-1206(10)60424-3","volume":"100","author":"K Bork","year":"2008","unstructured":"Bork K, Bygum A, Hardt J. Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Ann Allergy Asthma Immunol. 2008;100(2):153\u201361.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"9","key":"4280_CR11","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1056\/NEJM197208312870907","volume":"287","author":"AL Sheffer","year":"1972","unstructured":"Sheffer AL, Austen KF, Rosen FS. Tranexamic acid therapy in hereditary angioneurotic edema. N Engl J Med. 1972;287(9):452\u201354.","journal-title":"N Engl J Med"},{"issue":"6","key":"4280_CR12","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1080\/17512433.2016.1182425","volume":"9","author":"H Farkas","year":"2016","unstructured":"Farkas H. Icatibant as acute treatment for hereditary angioedema in adults. Expert Rev Clin Pharmacol. 2016;9(6):779\u201388.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"2","key":"4280_CR13","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.jaip.2014.09.001","volume":"3","author":"TJ Craig","year":"2015","unstructured":"Craig TJ, et al. Characterization of anaphylaxis after ecallantide treatment of hereditary angioedema attacks. J Allergy Clin Immunol Pract. 2015;3(2):206\u201312.e4.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"4280_CR14","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa0905079","volume":"363","author":"M Cicardi","year":"2010","unstructured":"Cicardi M, et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med. 2010;363(6):523\u201331.","journal-title":"N Engl J Med"},{"issue":"6","key":"4280_CR15","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.anai.2010.04.012","volume":"104","author":"RJ Levy","year":"2010","unstructured":"Levy RJ, et al. EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol. 2010;104(6):523\u201329.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"4280_CR16","doi-asserted-by":"crossref","unstructured":"Bouillet L, et al. Disease expression in women with hereditary angioedema. Am. J. Obstet Gynecol. 2008;199(5):484.e1\u20134.","DOI":"10.1016\/j.ajog.2008.04.034"},{"issue":"1","key":"4280_CR17","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.iac.2022.05.011","volume":"43","author":"MA Riedl","year":"2023","unstructured":"Riedl MA. Hereditary angioedema during pregnancy: considerations in management. Immunol Allergy Clin N Am. 2023;43(1):145\u201357.","journal-title":"Immunol Allergy Clin N Am"},{"issue":"1","key":"4280_CR18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ejogrb.2010.05.008","volume":"152","author":"I Czaller","year":"2010","unstructured":"Czaller I, et al. The natural history of hereditary angioedema and the impact of treatment with human C1-inhibitor concentrate during pregnancy: a long-term survey. Eur J Obstet, Gynecol, Reprod Biol. 2010;152(1):44\u201349.","journal-title":"Eur J Obstet, Gynecol, Reprod Biol"},{"key":"4280_CR19","doi-asserted-by":"crossref","unstructured":"Martinez-Saguer I, et al. Characterization of acute hereditary angioedema attacks during pregnancy and breast-feeding and their treatment with C1 inhibitor concentrate. Am. J. Obstet Gynecol. 2010;203(2):131.e1\u20137.","DOI":"10.1016\/j.ajog.2010.03.003"},{"key":"4280_CR20","unstructured":"CADTH common Drug Reviews, in clinical review report Lanadelumab (Takhzyro): (shire Pharma Canada ULC): indication: for routine prevention of attacks of hereditary angioedema in adolescents and adults. Can Agency Drugs Technol Health. 2020. Copyright \u00a9 2020 Canadian Agency for Drugs and Technologies in Health.: Ottawa (ON)."},{"issue":"3","key":"4280_CR21","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/s12016-021-08863-4","volume":"60","author":"M Kulkarni","year":"2021","unstructured":"Kulkarni M, Travers JB, Rohan C. High estrogen States in hereditary angioedema: a Spectrum. Clin Rev Allergy Immunol. 2021;60(3):396\u2013403.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"12","key":"4280_CR22","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1159\/000531074","volume":"184","author":"D Eyice Karabacak","year":"2023","unstructured":"Eyice Karabacak D, et al. How does pregnancy and type of delivery affect the clinical course of hereditary angioedema? Int Arch Allergy Immunol. 2023;184(12):1216\u201324.","journal-title":"Int Arch Allergy Immunol"},{"issue":"9","key":"4280_CR23","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1097\/OGX.0000000000000941","volume":"76","author":"KEB Chair II","year":"2021","unstructured":"Chair KEB II, Betschel SD. Hereditary angioedema in pregnancy. Obstet Gynecol Surv. 2021;76(9):566\u201374.","journal-title":"Obstet Gynecol Surv"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04280-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04280-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04280-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:37:30Z","timestamp":1781635050000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04280-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,21]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4280"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04280-y","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,21]]},"assertion":[{"value":"12 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our study was approved by the cantonal ethics committee (BASEC Nr. 2023\u201301329).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All participants gave their written informed consent. We also obtained the consent to publish the first case of Lanadelumab use during pregnancy.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Marine Casanova declares not having competing interests. Marie Charlotte Br\u00fcggen reports grants (not for the current project) from LEO foundation, LEO Pharma, Swiss National Science Foundation, Innovation Pool, GSK, Astra Zeneca; speaker and\/or consulting fees from Sanofi, Almirall, GSK, LEO Pharma and Abbvie. Walter Alfred Wuillemin reports receiving grants to the institution and lecture fees from Takeda, BioCryst, CSL Behring and KalVista. Christina Weber-Chrysochoou was taking part of advisory boards and was a speaker for Takeda, BioCryst, CSL Behring, Otsuka, Stallergenes, Menarini and KalVista.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"111"}}